Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
Phase 4
Completed
- Conditions
- ThrombocytopeniaIdiopathic Thrombocytopenic Purpura
- Interventions
- Biological: romiplostim
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 169
- Registration Number
- NCT00907478
20070360 Incident Dialysis
Phase 4
Completed
- Conditions
- Secondary HyperparathyroidismChronic Kidney Disease
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 313
- Registration Number
- NCT00803712
Panitumumab in Children With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Biological: Panitumumab
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT00658658
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
The SPECTRA Study
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT00537667
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
Phase 3
Completed
- Conditions
- OsteopeniaOsteoporosis
- Interventions
- Biological: Denosumab
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4550
- Registration Number
- NCT00523341
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Phase 3
Completed
- Conditions
- Thrombocytopenic PurpuraIdiopathic Thrombocytopenic PurpuraThrombocytopenia
- Interventions
- Biological: Romiplostim
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 407
- Registration Number
- NCT00508820
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 161
- Registration Number
- NCT00479817
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 204
- Registration Number
- NCT00456092
- Locations
- 🇬🇧
Chapel Allerton Hospital, Leeds, United Kingdom
🇬🇧Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
🇨🇦Credit Valley Rheumatology, Mississauga, Ontario, Canada
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
Phase 3
Terminated
- Conditions
- AnemiaChronic Kidney DiseaseKidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 116
- Registration Number
- NCT00436748
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- Drug: AMG 102 at 20 mg/kgDrug: AMG 102 at 10 mg/kg
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT00422019
© Copyright 2025. All Rights Reserved by MedPath